{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:39:25Z","timestamp":1792611565127,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.autrev.2024.103647","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T22:56:33Z","timestamp":1727564193000},"page":"103647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Indian Rheumatology Association guidelines for the management of ANCA associated vasculitis"],"prefix":"10.1016","volume":"23","author":[{"given":"Aadhaar","family":"Dhooria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.S.R.S.N.K.","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durga Prasanna","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benzeeta","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Adarsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saket","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv Ranjan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arghya","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashish","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nupoor","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joydeep","family":"Samanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengappa","family":"Kavadichanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahajal","family":"Dhooria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Jois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banwari","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canchi","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineeta","family":"Shobha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.G.","family":"Dharmanand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2024.103647_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international Chapel Hill consensus conference nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103647_bb0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","article-title":"Giant-cell granuloma of the respiratory tract (Wegener\u2019s granulomatosis)","volume":"2","author":"Walton","year":"1958","journal-title":"Br Med J"},{"key":"10.1016\/j.autrev.2024.103647_bb0015","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/ard.2007.071936","article-title":"Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force","volume":"67","author":"Mukhtyar","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103647_bb0020","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103647_bb0025","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103647_bb0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103647_bb0035","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.24634","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2024.103647_bb0040","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00296-018-3996-2","article-title":"Guidelines for management of rheumatic diseases in developing countries from basics to real-world situation: relevance, need, and processes for development","volume":"38","author":"Misra","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2024.103647_bb0045","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2024.103647_bb0050","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/jcp.56.10.775","article-title":"Audit of the clinical usefulness of a rapid qualitative ELISA screen for anti-myeloperoxidase and anti-proteinase 3 antibodies in the assessment of patients with suspected vasculitis","volume":"56","author":"Aslam","year":"2003","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.autrev.2024.103647_bb0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0022-1759(90)90350-5","article-title":"An ELISA for the detection of anti-neutrophil cytoplasm antibodies (ANCA)","volume":"127","author":"Rasmussen","year":"1990","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.autrev.2024.103647_bb0060","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2249.1995.tb05577.x","article-title":"Screening for anti-neutrophil cytoplasmic antibodies (ANCA): is indirect immunofluorescence the method of choice?","volume":"99","author":"Baslund","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2024.103647_bb0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.7326\/0003-4819-111-1-28","article-title":"Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis","volume":"111","author":"Nolle","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2024.103647_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-1759(96)00111-1","article-title":"Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays","volume":"196","author":"Hagen","year":"1996","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.autrev.2024.103647_bb0075","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/annrheumdis-2016-209507","article-title":"Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays","volume":"76","author":"Damoiseaux","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103647_bb0080","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","article-title":"Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis","volume":"13","author":"Bossuyt","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2024.103647_bb0085","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103647_bb0090","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103647_bb0095","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103647_bb0100","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103647_bb0105","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/acr2.11274","article-title":"Comparison of two rituximab induction regimens for antineutrophil cytoplasm antibody\u2013associated vasculitis: systematic review and meta-analysis","volume":"3","author":"B\u00e9nard","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2024.103647_bb0110","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/ket489","article-title":"Induction treatment of ANCA-associated vasculitis with a single dose of rituximab","volume":"53","author":"Turner-Stokes","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2024.103647_bb0115","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00005792-197311000-00002","article-title":"Wegener\u2019s granulomatosis: studies in eighteen patients and a review of the literature","volume":"52","author":"Fauci","year":"1973","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2024.103647_bb0120","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q","article-title":"Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study","volume":"41","author":"Haubitz","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103647_bb0125","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"De Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2024.103647_bb0130","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103647_bb0135","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/ndt\/gfm780","article-title":"Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement","volume":"23","author":"Hu","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2024.103647_bb0140","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103647_bb0145","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.11801018","article-title":"Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: randomized, controlled trial","volume":"14","author":"Tuin","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2024.103647_bb0150","article-title":"A randomized controlled trial of mycophenolate mofetil versus cyclophosphamide for induction therapy in ANCA associated systemic vasculitis with renal involvement","volume":"27","author":"Chen","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2024.103647_bb0155","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103647_bb0160","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/art.34547","article-title":"Brief report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Faurschou","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103647_bb0165","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103647_bb0170","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103647_bb0175","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103647_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185880","article-title":"Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: a randomised trial","volume":"12","author":"Maritati","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2024.103647_bb0185","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","article-title":"Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener\u2019s granulomatosis","volume":"46","author":"Metzler","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2024.103647_bb0190","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2024.103647_bb0195","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1093\/ndt\/gfab357","article-title":"Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis","volume":"37","author":"Berti","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2024.103647_bb0200","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener\u2019s granulomatosis","volume":"352","author":"Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103647_bb0205","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MD.0000000000000020","article-title":"Granulomatosis with polyangiitis (Wegener\u2019s): impact of maintenance therapy duration","volume":"93","author":"Springer","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2024.103647_bb0210","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/rheumatology\/kex281","article-title":"Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data","volume":"56","author":"de Joode","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2024.103647_bb0215","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/ndt\/gfw211","volume":"31","author":"Sanders","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2024.103647_bb0220","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103647_bb0225","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103647_bb0230","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2024.103647_bb0235","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103647_bb0240","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/rheumatology\/35.11.1150","article-title":"Intravenous immunoglobulin as sole therapy for systemic vasculitis","volume":"35","author":"Jayne","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2024.103647_bb0245","doi-asserted-by":"crossref","first-page":"C35","DOI":"10.1159\/000088313","article-title":"Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis","volume":"102","author":"Ito-Ihara","year":"2006","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.autrev.2024.103647_bb0250","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.39472","article-title":"Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: a French nationwide study of ninety-two patients","volume":"68","author":"Crickx","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103647_bb0255","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s00415-014-7618-y","article-title":"Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss syndrome): a multicenter, double-blind trial","volume":"262","author":"Koike","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2024.103647_bb0260","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.23147","article-title":"Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients","volume":"58","author":"Martinez","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103647_bb0265","first-page":"1124","article-title":"Treatment with intravenous immunoglobulin in the vasculitis ANCA positive. 27 cases studied in a single reference Centre","volume":"77","author":"Aviles Mendez","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103647_bb0270","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"QJM"},{"key":"10.1016\/j.autrev.2024.103647_bb0275","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/0140-6736(91)92797-6","article-title":"Treatment of systemic vasculitis with pooled intravenous immunoglobulin","volume":"337","author":"Jayne","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103647_bb0280","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.1995.tb02268.x","article-title":"Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin","volume":"101","author":"Richter","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2024.103647_bb0285","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ndt\/gfq360","article-title":"Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener\u2019s granulomatosis--a clinical randomized controlled trial","volume":"26","author":"Szpirt","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2024.103647_bb0290","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2024.103647_bb0295","doi-asserted-by":"crossref","DOI":"10.1038\/ki.2013.131","article-title":"Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear","volume":"84","author":"Walsh","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2024.103647_bb0300","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103647_bb0305","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2024.103647_bb0310","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2024.103647_bb0315","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"RITAZAREM co-investigators. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103647_bb0320","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2024.103647_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037626","article-title":"Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides","volume":"7","author":"Venhoff","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2024.103647_bb0330","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.22679","article-title":"Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients","volume":"57","author":"Cohen","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103647_bb0335","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/art.23198","article-title":"Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients","volume":"58","author":"Ribi","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103647_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102737","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systematic literature review","volume":"20","author":"Akiyama","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103647_bb0345","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103647_bb0350","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103647_bb0355","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","article-title":"Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial","volume":"69","author":"Pu\u00e9chal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103647_bb0360","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T16:10:15Z","timestamp":1731255015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224001381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":72,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1568997224001381"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103647","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indian Rheumatology Association guidelines for the management of ANCA associated vasculitis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103647"}}